Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Jeevan Scientific Technology's current ratio for the quarter that ended in Mar. 2026 was 2.51.
Jeevan Scientific Technology has a current ratio of 2.51. It generally indicates good short-term financial strength.
The historical rank and industry rank for Jeevan Scientific Technology's Current Ratio or its related term are showing as below:
BOM:538837'
s Current Ratio Range Over the Past 10 Years
Min: 0.8 Med: 1.95 Max: 2.68
Current: 2.51
During the past 13 years, Jeevan Scientific Technology's highest Current Ratio was 2.68. The lowest was 0.80. And the median was 1.95.
BOM:538837's Current Ratio is ranked worse than 62.01% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs BOM:538837: 2.51
Jeevan Scientific Technology (BOM:538837) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Jeevan Scientific Technology Current Ratio Related Terms
Jeevan Scientific Technology Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:538837 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Jeevan Scientific Technology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jeevan Scientific Technology Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jeevan Scientific Technology's Current Ratio distribution charts can be found below:
* The bar in red indicates where Jeevan Scientific Technology's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jeevan Scientific Technology (BOM:538837) has a Current Ratio of 2.51 as of Mar. 2026. This is 29% above median its historical median of 1.95. Over the past decade, Jeevan Scientific Technology's Current Ratio has ranged from 0.80 to 2.68. According to the industry distribution chart, Jeevan Scientific Technology ranks #875 out of 1411 companies in the Biotechnology industry, placing it in the top 62%.
Is Jeevan Scientific Technology's Current Ratio too high?
Jeevan Scientific Technology's current Current Ratio of 2.51 is 29% above median its 10-year median of 1.95. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 2.68. The Biotechnology industry median Current Ratio is 3.88. Jeevan Scientific Technology's value of 2.51 is 35.3% below this industry median. Based on the distribution chart, Jeevan Scientific Technology ranks #875 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jeevan Scientific Technology has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jeevan Scientific Technology's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jeevan Scientific Technology ranks #875 out of 1411 companies for Current Ratio. This places Jeevan Scientific Technology in the lower half of its industry. The industry median Current Ratio is 3.88. Jeevan Scientific Technology's value of 2.51 is 35.3% below this benchmark. Historically, Jeevan Scientific Technology's own Current Ratio has ranged from 0.80 to 2.68 over the past decade. While the company's 10-year median is 1.95 vs. the industry median of 3.88, Jeevan Scientific Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jeevan Scientific Technology's current Current Ratio of 2.51 is 35.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jeevan Scientific Technology's current Current Ratio is 2.51, which is 29% above median its own 10-year median of 1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeevan Scientific Technology stock overvalued right now?
Based on GuruFocus' analysis, Jeevan Scientific Technology (BOM:538837) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹61.75, compared to a current price of ₹72.77 — trading 17.8% above its estimated fair value. The current Current Ratio is 2.51, which is 29% above median its 10-year median of 1.95 and 35.3% below the Biotechnology industry median of 3.88. Jeevan Scientific Technology's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Jeevan Scientific Technology (BOM:538837), the current Current Ratio is 2.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jeevan Scientific Technology (BOM:538837) Overvalued in 2026?
Based on GuruFocus' analysis, Jeevan Scientific Technology stock appears to be overvalued.
The current stock price of ₹72.77 is trading 17.8% above its estimated GF Value™ of ₹61.75.
GuruFocus considers Jeevan Scientific Technology to be Modestly Overvalued.
Key valuation signals for BOM:538837:
Current Ratio: 2.51 (29% above median its 10-year median of 1.95)
GF Value™: ₹61.75 vs. price of ₹72.77 (17.8% above fair value)
Industry Position: 35.3% below the Biotechnology median (#875 of 1411)
No single metric tells the full story. See the BOM:538837 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jeevan Scientific Technology Ltd is an India-based company engaged in providing clinical research and data management services. Jeevan Scientific is an independent clinical contract research organization, offering reliable, cost-effective, and technology-driven clinical research solutions to various clients across the globe. Its services offer high-value testing services, including bioanalytical services for small and large molecules, ranging across generics, biosimilars, and other new drugs. It operates in a single segment, namely clinical research services.
65GF Score
Get the complete analysis for BOM:538837
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538837 has been successfully added to your 
